CORC

在结果中检索

CORC

浏览/检索结果: 共166条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers 期刊论文
CANCER LETTERS, 2024, 卷号: 582, 页码: 15
作者:  Lu, Xuxiu;  Yu, Rilei;  Li, Zhen;  Yang, Mengke;  Dai, Jiajia
收藏  |  浏览/下载：2/0  |  提交时间：2024/04/07
A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Lu, S.;  Zhang, Y.;  Zhang, G.;  Zhou, J.;  Cang, S.
收藏  |  浏览/下载：19/0  |  提交时间：2022/12/23
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong
收藏  |  浏览/下载：15/0  |  提交时间：2022/12/23
Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2021
作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo
收藏  |  浏览/下载：58/0  |  提交时间：2022/02/14
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang
收藏  |  浏览/下载：58/0  |  提交时间：2022/01/18
Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei
收藏  |  浏览/下载：17/0  |  提交时间：2022/01/04
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun
收藏  |  浏览/下载：35/0  |  提交时间：2021/11/01
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
收藏  |  浏览/下载：70/0  |  提交时间：2021/06/11
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文
THORACIC CANCER, 2021, 页码: 9
作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu
收藏  |  浏览/下载：18/0  |  提交时间：2021/05/24

©版权所有 ©2017 CSpace - Powered by CSpace